Briefcase Email Alerts Downloads Snapshot RSS Email Printed Materials Print this page

Achieve

Press Releases


 
Press Releases
  Date Title and Summary View
Jan 11, 2010
CARLSBAD, Calif., Jan 11, 2010 (BUSINESS WIRE) — Regulus Therapeutics Inc., a company developing microRNA therapeutics, today announced the appointment of Zachary A. Zimmerman, Ph.D., as director of business development. Dr. Zimmerman will be responsible for business development and licensing, as well as managing external collaborations an...
Dec 17, 2009
CARLSBAD, Calif., Dec. 17, 2009 – Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. co...
Dec 14, 2009
Regulus Therapeutics Inc. presents: “MicroRNA: The Year in Review and a Look Ahead” The replay of our webinar is now available: http://www.videonewswire.com/event.asp?id=64631
Dec 9, 2009
CARLSBAD, Calif., Dec. 9, 2009 – Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic ...
Oct 28, 2009
CARLSBAD, Calif. & CAMBRIDGE, Mass–Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Ser...
Sep 17, 2009
CARLSBAD, Calif. & CAMBRIDGE, Mass.–Sep. 17, 2009– Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the Japan Patent Office (JPO) has notified the Max Planck Society of its intent to grant a patent from the Tuschl III patent ...
Sep 16, 2009
CARLSBAD, Calif., September 17, 2009 – Regulus Therapeutics Inc., a leading microRNA therapeutics company, today announced the appointment of Hubert C. Chen, M.D., as Vice President of Translational Medicine.  At Regulus, Dr. Chen will be responsible for leading the translation of the important biological discoveries in ...
Aug 11, 2009
Cambridge, Mass. and Carlsbad, Calif. – August 11, 2009 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Regulus Therapeutics Inc., a leading microRNA therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a notice of allowance...
Jul 7, 2009
CAMBRIDGE, Mass. and CARLSBAD, Calif., September 7, 2007 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today the launch of Regulus Therapeutics LLC, a joint venture focused on the discovery, development, and commercialization of microRNA (miRNA) therapeutics. Because miRNAs regulate ...
May 14, 2009
CARLSBAD, Calif., May 14, 2009 – Regulus Therapeutics Inc. today announced that it achieved the initial milestone with GlaxoSmithKline (GSK) as part of their ongoing worldwide strategic alliance established to discover, develop and market novel microRNA-based therapeutics to treat inflammatory diseases. The two companies are ...
Page: FirstPrevious ...
20
NextLast
= add release to Briefcase